Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx
@CARTTherapy
Followers
4K
Following
748
Media
1K
Statuses
4K
Cellular & Gene Therapy Program @ KFSHRC KSA #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy
Joined December 2019
Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33) | JCO Precision Oncology
ascopubs.org
0
4
17
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia | Journal of Clinical Oncology
ascopubs.org
On June 6, 2024, the US Food and Drug Administration (FDA) approved imetelstat (RYTELO, Geron) for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent...
0
6
12
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia | Journal of Clinical Oncology
ascopubs.org
On June 6, 2024, the US Food and Drug Administration (FDA) approved imetelstat (RYTELO, Geron) for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent...
0
6
12
Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study
ashpublications.org
Key Points. HCT with HLA-matched and -mismatched donors can yield satisfactory long-term clinical and neurological outcomes in PNP-deficient patients.Early
0
1
4
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation | Journal of Clinical Oncology
ascopubs.org
PURPOSEThe likelihood of finding a human leukocyte antigen (HLA)–matched unrelated donor (MUD) for hematopoietic cell transplantation can be predicted using a donor search prognosis score. Patients...
0
0
1
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation | Journal of Clinical Oncology
ascopubs.org
PURPOSEThe likelihood of finding a human leukocyte antigen (HLA)–matched unrelated donor (MUD) for hematopoietic cell transplantation can be predicted using a donor search prognosis score. Patients...
0
1
11
The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma
ashpublications.org
Key pointsAcquisition of Mann-type glycans is a tumor-specific environmental pressure indicative of aggressive GCB-DLBCL with its origin related to FL.Mann
0
2
11
Impact of inflammatory cytokine polymorphisms on the progression of myelodysplastic syndromes | Annals of Hematology https://t.co/bNQN3ZKAjI
link.springer.com
Annals of Hematology - Chronic inflammation is increasingly recognized as a key contributor to tumorigenesis, promoting genomic instability, immune evasion, and malignant transformation....
1
1
4
Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia
ashpublications.org
Key Points. ‘Off-the-shelf’ bispecific CD133-CD19 CAR-iNKT cells eradicate CAR antigen-high and -low medullary and leptomeningeal KMT2Ar ALLCAR and CAR-ant
0
2
17
Statins Enhance the Efficacy of Pegylated Interferon-α2 in Philadelphia-Negative Chronic Myeloproliferative Neoplasms
ashpublications.org
Key PointsStatins enhance treatment responses in IFN-treated patients with MPN, allowing for lower IFN doses and faster CHR.A dose-response relationship wa
0
1
1
Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients
ashpublications.org
HHV-6 reactivation in CAR T-cell recipients is reported to be rare. Our patient cohort (n=119) experienced a seven-fold higher incidence of viraemia than a
0
0
3
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML
ashpublications.org
Abstract. FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute
0
5
40
The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort
ashpublications.org
Key Points. The W&W approach was used in more than one third of children with JMML. 86% of these patients achieved long-term survival without HSCT.Part
0
0
4
Azacitidine as therapy for VEXAS syndrome
ashpublications.org
How should patients with VEXAS (an acronym for vacuoles [in myeloid and erythroid precursors], E1 enzyme, X-linked, autoinflammatory, somatic) syndrome be
0
0
2
Efficacy and Safety of Allogeneic HCT in Curing Sickle Cell Disease: A Systematic Review and Meta-Analysis of Single-Arm Studies - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
astctjournal.org
Sickle cell disease (SCD) is a severe yet common genetic blood disorder affecting 20 to 25 million people worldwide [1], with around 300,000 infants born annually with the condition, particularly in...
0
1
8
Pre-HCT Ruxolitinib in Transplant-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
0
0
1
Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
astctjournal.org
Chimeric antigen receptor T-cell therapy (CAR-T) has significantly improved outcomes for relapsed and/or refractory B-cell malignancies. Commercially available CD-19 directed CAR-T products include...
0
3
14
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus | New England Journal of Medicine VERY IMPRESSIVE WORK https://t.co/agKM0t9XAM
nejm.org
In patients with refractory systemic lupus erythematosus, in vivo generation of CD19 CAR T cells by means of lipid nanoparticles led to B-cell depletion, reduced disease activity, and no major toxi...
0
4
17
Haploidentical vs. Matched Sibling Donor HCT in Racially Diverse Pediatric and AYA Patients with Hematologic Malignancies: A Single-Center Comparison -
astctjournal.org
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for pediatric patients with hematologic malignancies. Human leukocyte antigen (HLA)-matched sibling donors...
0
0
2
Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axi-cel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma -
0
0
2